Arvinas

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Arvinas and other ETFs, options, and stocks.

About ARVN

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. 

CEO
Randy Teel
CEORandy Teel
Employees
246
Employees246
Headquarters
New Haven, Connecticut
HeadquartersNew Haven, Connecticut
Founded
2013
Founded2013
Employees
246
Employees246

ARVN Key Statistics

Market cap
655.60M
Market cap655.60M
Price-Earnings ratio
-8.44
Price-Earnings ratio-8.44
Dividend yield
Dividend yield
Average volume
870.71K
Average volume870.71K
High today
$10.80
High today$10.80
Low today
$10.24
Low today$10.24
Open price
$10.55
Open price$10.55
Volume
1.13M
Volume1.13M
52 Week high
$14.51
52 Week high$14.51
52 Week low
$5.90
52 Week low$5.90

Stock Snapshot

The current Arvinas(ARVN) stock price is $10.36, with a market capitalization of 655.6M. The stock trades at a price-to-earnings (P/E) ratio of -8.44.

As of 2026-05-07, Arvinas(ARVN) stock has fluctuated between $10.24 and $10.80. The current price stands at $10.36, placing the stock +1.2% above today's low and -4.1% off the high.

Arvinas(ARVN) shares are trading with a volume of 1.13M, against a daily average of 870.71K.

In the last year, Arvinas(ARVN) shares hit a 52-week high of $14.51 and a 52-week low of $5.90.

In the last year, Arvinas(ARVN) shares hit a 52-week high of $14.51 and a 52-week low of $5.90.

ARVN News

Benzinga 3d
Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy

The approval covers estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or m...

Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy
TipRanks 3d
Arvinas price target raised to $24 from $21 at Citi

Citi raised the firm’s price target on Arvinas (ARVN) to $24 from $21 and keeps a Buy rating on the shares after the company received FDA approval of Veppanu fo...

TipRanks 6d
Arvinas Gains First FDA Approval for Breast Cancer Drug

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Analyst ratings

56%

of 18 ratings
Buy
55.6%
Hold
38.9%
Sell
5.6%

More ARVN News

Seeking Alpha 6d
Pfizer, Arvinas breast cancer therapy approved by the FDA

The U.S. Food and Drug Administration on Friday approved vepdegestrant, a breast cancer therapy developed by Pfizer (PFE) and Arvinas (ARVN) under the brand nam...

Pfizer, Arvinas breast cancer therapy approved by the FDA

People also own

Based on the portfolios of people who own ARVN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.